Moderna and Carisma Therapeutics partner to develop CAR-M therapeutics
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
This is a shot in the arm for the vaccine manufacturers
The interim data combines three mRNAs into one therapy injected directly into the tumour
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
Subscribe To Our Newsletter & Stay Updated